India’s drug pricing regulator has allowed pharmaceutical companies to increase the ceiling price of essential medicine heparin by how much per cent until December 31, 2020?

India’s drug pricing regulator has allowed pharmaceutical companies to increase the ceiling price of essential medicine heparin by how much per cent until December 31, 2020? Correct Answer 50

Option 4 is correct i.e. 50%.

  • India’s drug pricing regulator has allowed pharmaceutical companies to increase the ceiling price of essential medicine heparin by 50% until December 31, 2020.
  • Heparin is a blood thinner that has long been used in patients vulnerable to blood clots in their legs, lungs, heart or other body parts.
  • It is used to reduce their risk of heart attacks, strokes and pulmonary embolism.

Related Questions

In the question below, are given a statement followed by three courses of actions numbered I, II and III. On the basis of the information given, you have to assume everything in the statement to be true, and then decide which of the suggested courses of action logically follow(s) for pursuing. Statement: India’s pharmaceutical sector is now popping out from a shell and making a remarkable recovery. Actually, it has been facing several regulatory challenges in the forms of a recast of foreign direct investment (FDI) policy, pricing policy in the US generics market, patent protection, regulatory approvals and compulsory licensing. Also limited new product launches in the generics space, GST introduction and higher costs associated with regulatory compliance have hurt the sector. Courses of action: I. The government has been engrossed more in policy making and taking resilient decisions for the concerns of the pharma industry. Recently, the government proposed to introduce a new price index for pharmaceutical products, which would serve as a benchmark for determining prices of all medicines sold in the country. II. Meanwhile, pharma companies’ constant investments in R&D have enabled them to develop a basket of robust products for markets across the world. In international markets, pricing pressure on generics sold in the US has eased and this is likely to support the sector. III. Domestic pharma sales grew to Rs. 10,583 crore in May 2018 from Rs. 9,549 crore in the same month last year. The recent clearance by the US Food and Drug Administration to Sun Pharma’s manufacturing plant at Halol in Gujarat brings to an end a two-year import ban it had imposed on the company over quality issues. This is likely to increase sales for the company.
The question below is followed by two statements I and II. You have to determine whether the data given is sufficient for answering the question. You should use the data and your knowledge of mathematics to choose the best possible answer.  Belly has some coins out of which some are of 25 Cent and Some are of 50 Cent. If he has a total of 250 coins, how many coins does he have of 25 Cent? I) Belly has three times as many as 50 Cent coins as 25 Cent coins. II) Belly has 20 more 25 cent coins than the 50 Cent coin.